<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: White light endoscopy with random biopsies is the standard for detection of <z:mpath ids='MPATH_167'>intestinal metaplasia</z:mpath> (IM) and <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (BO) </plain></SENT>
<SENT sid="1" pm="."><plain>Narrow band imaging (NBI) highlights surface patterns that correlate with IM and <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in BO </plain></SENT>
<SENT sid="2" pm="."><plain>OBJECTIVE: To compare high-definition white light (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-WLE) and NBI for detection of IM and <z:hpo ids='HP_0002664'>neoplasia</z:hpo> in BO </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: International, randomised, crossover trial comparing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-WLE and NBI </plain></SENT>
<SENT sid="4" pm="."><plain>Patients referred for BO screening/surveillance at three tertiary referral centres were prospectively enrolled and randomised to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-WLE or NBI followed by other procedures in 3-8 weeks </plain></SENT>
<SENT sid="5" pm="."><plain>During <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-WLE, four quadrant biopsies every 2 cm, together with targeted biopsies of visible lesions (Seattle protocol), were obtained </plain></SENT>
<SENT sid="6" pm="."><plain>During NBI examination, mucosal and vascular patterns were noted and targeted biopsies were obtained </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> biopsies were read by a single expert gastrointestinal pathologist in a blinded fashion </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: 123 patients with BO (mean age 61; 93% male; 97% Caucasian) with mean circumferential and maximal extents of 1.8 and 3.6 cm, respectively, were enrolled </plain></SENT>
<SENT sid="9" pm="."><plain>Both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-WLE and NBI detected 104/113 (92%) patients with IM, but NBI required fewer biopsies per patient (3.6 vs 7.6, p&lt;0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>NBI detected a higher proportion of areas with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> (30% vs 21%, p=0.01) </plain></SENT>
<SENT sid="11" pm="."><plain>During examination with NBI, <z:hpo ids='HP_0000001'>all</z:hpo> areas of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> had an irregular mucosal or vascular pattern </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: NBI targeted biopsies can have the same IM detection rate as an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-WLE examination with the Seattle protocol while requiring fewer biopsies </plain></SENT>
<SENT sid="13" pm="."><plain>In addition, NBI targeted biopsies can detect more areas with <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="14" pm="."><plain>Regular appearing NBI surface patterns did not harbour high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath>/<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, suggesting that biopsies could be avoided in these areas </plain></SENT>
</text></document>